Already on the Euronext stock exchange, liver disease biotech GenFit has made the jump to the more lucrative Nasdaq with a $135 million IPO.
The French biotech, seen as one of a host of leading NASH players with phase 3 assets designed to help hit fatty livers caused by obesity, got a few million dollars more than it had first aimed for and will now trade as $GNFT in the U.S.
Genfit is developing lead drug elafibranor for both NASH (nonalcoholic steatohepatitis) and primary biliary cholangitis (PBC), an autoimmune disease of the liver. Elafibranor is a dual agonist of the PPAR-alpha and PPAR-delta, which are nuclear receptors, a type of protein found inside cells that play a role in cellular metabolism, among other things.
Other players in this space, including Intercept, Gilead, Shire, Bristol-Myers Squibb and NGM Bio, are going after several different targets to hit liver fat; many have suffered setbacks and challenges in testing, but all are hopeful of getting in on a market talked up as being worth tens of billions of dollars at peak.
Specifically, GenFit has earmarked $50 million of its IPO proceeds for the completion of its elafibranor program in NASH, “through to, at least, the submission of an NDA to the FDA and EMA and the launch of a Phase 4 [postmarket] clinical trial,” it said in a recent SEC filing.
And $15 million is also on the table for boosting its commercial infrastructure, while $35 million is for a planned phase 3 trial of elafibranor in PBC, which it hopes can compete with rival Intercept’s drug Ocaliva, which is also gunning for a NASH approval.
That leaves $6 million for research on combination therapies involving elafibranor and another $6 million for the development of Genfit’s in-vitro diagnostic test for NASH.
Data from its NASH phase 3 are slated for the end of the year. Meanwhile, big biotech rival Gilead announced Wednesday that it will be sharing a host of NASH data from across its shots on goal at the EASL liver disease conference in Vienna in mid-April.